Location of Repository

The K+ channels KCa3.1 and Kv1.3 as novel targets for asthma therapy

By Peter Bradding and Heike Wulff

Abstract

Asthma affects 10% of the UK population and is an important cause of morbidity and mortality at all ages. Current treatments are either ineffective or carry unacceptable side effects for a number of patients; in consequence, development of new approaches to therapy are important. Ion channels are emerging as attractive therapeutic targets in a variety of non-excitable cells. Ion channels conducting K+ modulate the activity of several structural and inflammatory cells which play important roles in the pathophysiology of asthma. Two channels of particular interest are the voltage-gated K+ channel Kv1.3 and the intermediate conductance Ca2+-activated K+ channel KCa3.1 (also known as IKCa1 or SK4). Kv1.3 is expressed in IFNγ-producing T cells while KCa3.1 is expressed in T cells, mast cells, macrophages, airway smooth muscle cells, fibroblasts and epithelial cells. Both channels play important roles in cell activation, migration and proliferation through the regulation of membrane potential and calcium signalling. We hypothesise that KCa3.1- and/or Kv1.3-dependent cell processes are one of the common denominators in asthma pathophysiology. If true, these channels might serve as novel targets for the treatment of asthma. Emerging evidence lends support to this hypothesis. Further validation through the study of the role these channels play in normal and asthmatic airway cell (patho)physiology and in vivo models will provide further justification for the assessment of small molecule blockers of Kv1.3 and KCa3.1 in the treatment of asthma

Topics: asthma, KCa3.1, Kv1.3, ion channel
Publisher: Wiley-Blackwell on behalf of The British Pharmacological Society
Year: 2003
DOI identifier: 10.1111/j.1476-5381.2009.00362.x
OAI identifier: oai:lra.le.ac.uk:2381/8030
Journal:

Suggested articles

Preview

Citations

  1. (1991). A Ca2(+)-activated K+ current in ras-transformed fibroblasts is absent from nontransformed cells.
  2. (1999). Activation of the human intermediate-conductance Ca(2+)-activated K(+) channel by 1-ethyl-2-benzimidazolinone is strongly Ca(2+)-dependent. doi
  3. and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. doi
  4. (2001). Calcium signaling mechanisms in T lymphocytes.
  5. (2006). CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. doi
  6. (2007). CRACM1, CRACM2, and CRACM3 are store-operated Ca2+ channels with distinct functional properties. doi
  7. (2006). Cytokines or their antagonists for the treatment of asthma. doi
  8. (2000). Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: A potential immunosuppressant. doi
  9. (2005). Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T Cells in autoimmune diseases. doi
  10. (2004). Dysfunctional Interaction of C/EBP{alpha} and the Glucocorticoid Receptor in Asthmatic Bronchial SmoothMuscle Cells. doi
  11. (1997). Extracellular ATP and UTP control the generation of reactive oxygen intermediates in human macrophages through the opening of a charybdotoxin-sensitive Ca2+-dependent K+ channel.
  12. (2008). Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. doi
  13. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. doi
  14. (2006). Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. doi
  15. (2009). Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. doi
  16. (2001). Opening of KCa3.1 channels (A) and hyperpolarisation of the plasma membrane (B) in a human peripheral blood-derived mast cell following IgE-dependent activation. Graphs reproduced with permission from Duffy et al, 2001; Copyright
  17. (2006). Orai1 is an essential pore subunit of the CRAC channel. doi
  18. (2006). p<0.05, ** p<0.01. ASM S/N–dependent migration in (A) is represented as 100% in (B). DMSO 0.1% was present in all conditions. Reproduced from Cruse et al.
  19. (1992). Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. doi
  20. (2005). Severe asthma in adults. doi
  21. (2005). STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane. doi
  22. (2006). Subcellular distribution of calcium-sensitive potassium channels (IK1) in migrating cells. doi
  23. (2007). The Ca(2+)-activated K(+) channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes. doi
  24. the epidermal growth factor receptor in epithelial repair in asthma. doi
  25. (1999). The fibroblast intermediate conductance K(Ca) channel, FIK, as a prototype for the cell growth regulatory function of the IK channel family. doi
  26. (2004). The global burden of asthma: executive summary of the GINA Dissemination Committee report. doi
  27. (2008). The intermediateconductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. doi
  28. (2003). The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. doi
  29. (1996). Transmembrane movement of the shaker K+ channel S4. doi
  30. (2001). Tsicopoulos A et al. doi
  31. (1993). Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.